Investment Plan for Europe: EIB backs Italian CNS drug developer Newron Pharmaceuticals with up to EUR 40m

The European Investment Bank (EIB) and Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), signed a financing agreement today, which will allow the Company to borrow up to EUR 40 million over the coming years, subject to achieving a set of agreed performance criteria.
Source: Investment Plan for Europe: EIB backs Italian CNS drug developer Newron Pharmaceuticals with up to EUR 40m – {feed_title}

X
X